Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.

Publikation

Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.

Wissenschaftlicher Artikel/Review - 10.10.2022

Papachristofilou Alexandros, Bedke Jens, Hayoz Stefanie, Schratzenstaller Ulrich, Pless Miklos, Hentrich Marcus, Krege Susanne, Lorch Anja, Aebersold Daniel-M, Putora Paul Martin, Berthold Dominik-R, Zihler Deborah, Zengerling Friedemann, Dieing Annette, Mueller Arndt-Christian, Schaer Corinne, Biaggi Christine, Gillessen Silke, Cathomas Richard

Zitation

Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold D, Putora P, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A, Schaer C, Biaggi C, Gillessen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23:1441-1450.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Oncol 2022; 23

Veröffentlichungsdatum

10.10.2022

eISSN (Online)

1474-5488

Seiten

1441-1450

Kurzbeschreibung/Zielsetzung

Standard treatment options for patients with stage IIA or stage IIB seminoma include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based combination chemotherapy. These options result in 3-year progression free survival rates of at least 90%, but bear risks for acute and late toxic effects, including secondary malignancies. We tested a novel approach combining de-escalated chemotherapy with de-escalated involved node radiotherapy, with the aim of reducing toxicity while preserving efficacy.